Subtopic Deep Dive
LRRK2 Mutations in Parkinson's Disease
Research Guide
What is LRRK2 Mutations in Parkinson's Disease?
LRRK2 mutations are the most common genetic cause of familial Parkinson's disease, with the G2019S variant augmenting kinase activity that drives lysosomal and autophagic dysfunction.
LRRK2 gene mutations, particularly G2019S, increase kinase activity two- to threefold, leading to phosphorylation of Rab GTPases essential for vesicular trafficking (Steger et al., 2016, 1035 citations). These mutations show variable worldwide penetrance, from 17% in Asian populations to 80% in North African cohorts (Healy et al., 2008, 1535 citations). Over 20 papers detail LRRK2's role in both familial and sporadic PD cases.
Why It Matters
LRRK2 mutations affect 1-2% of sporadic PD patients and up to 40% of familial cases in certain populations, positioning LRRK2 as a therapeutic target for kinase inhibitors (West et al., 2005, 1218 citations). Healy et al. (2008) quantified penetrance variations, guiding stratified trials. Klein and Westenberger (2012, 1337 citations) highlight LRRK2's overlap with idiopathic PD, enabling broad modulator development tested in SH-SY5Y models (Xicoy et al., 2017, 949 citations).
Key Research Challenges
Variable Genetic Penetrance
LRRK2 mutations exhibit penetrance from 17% to 80% across populations, complicating risk prediction (Healy et al., 2008, 1535 citations). Environmental modifiers remain unidentified. Genetic counseling requires refined models.
Rab GTPase Phosphorylation Specificity
LRRK2 phosphorylates a subset of 10 Rab GTPases, disrupting lysosomal function, but full substrate networks are incomplete (Steger et al., 2016, 1035 citations). Pathogenic versus physiological targets need differentiation. Inhibitor off-target effects pose risks.
Selective Kinase Inhibitor Design
G2019S boosts kinase activity two-fold, demanding brain-penetrant inhibitors without toxicity (West et al., 2005, 1218 citations). Clinical translation lags preclinical models. Biomarker development for patient selection is essential.
Essential Papers
Parkinson's disease
Bastiaan R. Bloem, Michael S. Okun, Christine Klein · 2021 · The Lancet · 3.2K citations
The Role of Oxidative Stress in Parkinson's Disease
Vera Dias, Eunsung Junn, M. Maral Mouradian · 2013 · Journal of Parkinson s Disease · 1.7K citations
Oxidative stress plays an important role in the degeneration of dopaminergic neurons in Parkinson's disease (PD). Disruptions in the physiologic maintenance of the redox potential in neurons interf...
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy, Mario Falchi, Sean S. O’Sullivan et al. · 2008 · The Lancet Neurology · 1.5K citations
Genetics of Parkinson's Disease
Christine Klein, Ana Westenberger · 2012 · Cold Spring Harbor Perspectives in Medicine · 1.3K citations
Fifteen years of genetic research in Parkinson's disease (PD) have led to the identification of several monogenic forms of the disorder and of numerous genetic risk factors increasing the risk to d...
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
Andrew B. West, Darren J. Moore, Saskia Biskup et al. · 2005 · Proceedings of the National Academy of Sciences · 1.2K citations
Mutations in the leucine-rich repeat kinase 2 gene ( LRRK2 ) cause late-onset Parkinson's disease (PD) with a clinical appearance indistinguishable from idiopathic PD. Initial studies suggest that ...
Parkinson disease-associated cognitive impairment
Dag Aarsland, Lucia Batzu, Glenda M. Halliday et al. · 2021 · Nature Reviews Disease Primers · 1.2K citations
Parkinson’s disease: etiopathogenesis and treatment
Joseph Jankovic, Eng King Tan · 2020 · Journal of Neurology Neurosurgery & Psychiatry · 1.1K citations
The concept of ‘idiopathic’ Parkinson’s disease (PD) as a single entity has been challenged with the identification of several clinical subtypes, pathogenic genes and putative causative environment...
Reading Guide
Foundational Papers
Start with West et al. (2005, 1218 citations) for kinase augmentation evidence, Healy et al. (2008, 1535 citations) for penetrance data, Klein and Westenberger (2012, 1337 citations) for genetic context.
Recent Advances
Steger et al. (2016, 1035 citations) details Rab phosphoproteome; Xicoy et al. (2017, 949 citations) validates SH-SY5Y models.
Core Methods
Kinase assays measure G2019S activity (West et al., 2005); phosphoproteomics profiles Rab substrates (Steger et al., 2016); case-control genotyping assesses penetrance (Healy et al., 2008).
How PapersFlow Helps You Research LRRK2 Mutations in Parkinson's Disease
Discover & Search
Research Agent uses searchPapers('LRRK2 G2019S Rab phosphorylation') to retrieve 50+ papers, then citationGraph on Steger et al. (2016) maps Rab substrate networks. findSimilarPapers expands to kinase inhibitor trials; exaSearch uncovers unpublished preprints.
Analyze & Verify
Analysis Agent applies readPaperContent to Healy et al. (2008) for penetrance data extraction, verifyResponse (CoVe) cross-checks mutation frequencies against Klein and Westenberger (2012). runPythonAnalysis plots kinase activity fold-changes from West et al. (2005) datasets with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in Rab GTPase coverage post-Steger et al. (2016), flags contradictions in penetrance estimates. Writing Agent uses latexEditText for inhibitor review sections, latexSyncCitations integrates 20 LRRK2 papers, latexCompile generates figures, exportMermaid visualizes mutation-pathway diagrams.
Use Cases
"Analyze LRRK2 kinase activity data from West 2005 across mutations"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas fold-change plots, matplotlib kinase curves) → statistical verification output with p-values and GRADE B rating.
"Write LaTeX review on LRRK2 Rab phosphorylation mechanisms"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Steger 2016 et al.) → latexCompile (full PDF with figures) → researcher gets camera-ready manuscript.
"Find GitHub code for SH-SY5Y LRRK2 inhibitor assays"
Research Agent → paperExtractUrls (Xicoy 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets assay scripts, pipelines, and replication notebooks.
Automated Workflows
Deep Research workflow runs searchPapers on 'LRRK2 mutations PD' → citationGraph → DeepScan (7-step: extract → verify → synthesize) → structured report on 50+ papers with GRADE tables. Theorizer generates hypotheses on Rab-LRRK2-lysosomal links from Steger et al. (2016) and West et al. (2005), outputting testable models via exportMermaid.
Frequently Asked Questions
What defines LRRK2 mutations in PD?
LRRK2 mutations like G2019S cause familial PD by increasing kinase activity two- to threefold, mimicking idiopathic forms (West et al., 2005, 1218 citations).
What methods study LRRK2 pathology?
Phosphoproteomics identifies Rab GTPase substrates (Steger et al., 2016, 1035 citations); SH-SY5Y cells model inhibitor effects (Xicoy et al., 2017, 949 citations).
What are key papers on LRRK2?
Healy et al. (2008, 1535 citations) map penetrance; West et al. (2005, 1218 citations) show augmented kinase; Steger et al. (2016, 1035 citations) reveal Rab targets.
What open problems exist?
Unresolved: full Rab substrate map, penetrance modifiers, selective inhibitors without toxicity (Klein and Westenberger, 2012).
Research Parkinson's Disease Mechanisms and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching LRRK2 Mutations in Parkinson's Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.